<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03653312</url>
  </required_header>
  <id_info>
    <org_study_id>REG-80-2015</org_study_id>
    <nct_id>NCT03653312</nct_id>
  </id_info>
  <brief_title>Neuromuscular Electrical Stimulation in Acute Ischemic Stroke</brief_title>
  <acronym>NESA</acronym>
  <official_title>Neuromuscular Electrical Stimulation in Acute Ischemic Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zealand University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zealand University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to examine the added effect of NeuroMuscular Electric Stimulation
      (NMES) in addition to exercise therapy in the acute phase of ischemic stroke.

      This randomized controlled trial includes 50 patients allocated to either control or
      intervention.

      The inclusion, test, training and re-test will be provided during the first 14 days after
      ictus, starting day 1 or 2 after ictus and a follow-up at day 90.

      The exercise training with external NMES is done with the patient every weekday for 12
      minutes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Stroke is the third most cause of disability in adults over 65 years of age worldwide. In
      2008, 30.7 million people had survived a stroke. Every year, there are about 14,000 new cases
      of stroke in Denmark and the number is expected to rise with about 40% by 2035, due to the
      increasing population of elderly. Stroke survivors have the worst odds of reporting severe
      disability and the greatest variety of individual domains of disability compared to a range
      of other diseases. Therefore, these patients have essential rehabilitation needs. Little is
      known about who will benefit from functional interventional rehabilitation and what kind of
      intervention is best.

      The purpose of the study is to examine the added effect of NeuroMuscular Electric Stimulation
      (NMES) in addition to exercise therapy in the acute phase of ischemic stroke.

      This RCT includes 50 patients allocated to either control or intervention. The inclusion,
      test, training and re-test will be provided during the first 14 days after ictus, starting
      day 1 after ictus and a follow-up at day 90.

      The exercise training with external NMES is done with the patient every weekday for 12
      minutes.

      If NMES increases functionality in acute stroke patients it would mean a greater degree of
      independence for individual patients and thus have the potential to improve on a major
      problem for society.

      By combining comorbidity, stroke severity, and other demographic data it might be possible to
      get a greater knowledge about who will benefit from the intervention and early rehabilitation
      and that will be the a step towards &quot;personalized medicine&quot; in stroke rehabilitation.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 27, 2018</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Actual">June 3, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel group, assessor blinded, randomized controlled trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>One blinded outcome assessor (physiotherapists) will perform measurements of functional capacity, patient reported outcome, and cognition. Statistical analysis will be performed by a blinded statistician and a blinded interpretation of the results will be performed before breaking the randomization code.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>The six Minute-Walk Test</measure>
    <time_frame>Primary endpoint: Change from baseline to 3 months. Secondary endpoint: Change from baseline to 2 weeks.</time_frame>
    <description>The six-minute walk test (6MWT) measures the distance an individual is able to walk over a total of six minutes on a hard, flat surface. The goal is for the individual to walk as far as possible in six minutes. The individual is allowed to self-pace and rest as needed as they traverse back and forth along a marked walkway.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fugl Meyer Assessment</measure>
    <time_frame>Primary endpoint: Change from baseline to 3 months. Secondary endpoint: Change from baseline to 2 weeks.</time_frame>
    <description>The Fugl-Meyer Assessment (FMA) is a stroke-specific, performance-based impairment index. It is designed to assess motor functioning, balance, sensation and joint functioning in patients with post-stroke hemiplegia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sit to stand</measure>
    <time_frame>Primary endpoint: Change from baseline to 3 months. Secondary endpoint: Change from baseline to 2 weeks.</time_frame>
    <description>Sit-to-stand is a mechanically demanding task demanding task</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Timed Up and Go</measure>
    <time_frame>Primary endpoint: Change from baseline to 3 months. Secondary endpoint: Change from baseline to 2 weeks.</time_frame>
    <description>The Timed Up and Go test (TUG) is a simple test used to assess a person's mobility and requires both static and dynamic balance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EuroQOL 5 domain</measure>
    <time_frame>Change from day 14 post ictus to day 90 post ictus.</time_frame>
    <description>A self-reported outcome measure of health-related quality of life, covering 5 dimensions (movement, personal care, everyday activities, pain/discomfort and anxiety/depression). Is translated and validated for use in a Danish population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>10 meter walk test</measure>
    <time_frame>Primary endpoint: Change from baseline to 3 months. Secondary endpoint: Change from baseline to 2 weeks.</time_frame>
    <description>The 10 Metre Walk Test is a performance measure used to assess walking speed in metres per second over a 10 meter distance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Montreal Cognitive Assessment (MoCA)</measure>
    <time_frame>Change from day 14 post ictus to day 90 post ictus.</time_frame>
    <description>The Montreal Cognitive Assessment (MoCA) was designed as a rapid screening instrument for mild cognitive dysfunction. It assesses different cognitive domains: attention and concentration, executive functions, memory, language, conceptual thinking, calculations, and orientation. Time to administer the MoCA is approximately 10 minutes. The total possible score is 30 points; a score of 26 or above is considered normal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Becks Depression Inventory</measure>
    <time_frame>Change from day 14 post ictus to day 90 post ictus.</time_frame>
    <description>Becks Depression Inventory is a 21-question multiple-choice self-report inventory, one of the most widely used psychometric tests for measuring the severity of depression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Guralnik</measure>
    <time_frame>Primary endpoint: Change from baseline to 3 months. Secondary endpoint: Change from baseline to 2 weeks.</time_frame>
    <description>Balance test assessed by the ability to stand for 10 seconds without support in each of the following positions: total feet, semitandem and full tandem</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Ischemic Stroke</condition>
  <condition>Neuromuscular Electrical Stimulation</condition>
  <condition>Exercise</condition>
  <arm_group>
    <arm_group_label>NMES</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 weeks (weekdays) of Neuromuscular Electrical Stimulation of the paretic lower limb during exercise.
Each exercise session will last for 12 minutes and will consist of either walk or sit and raise from a chair.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>training</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants will undergo 2 weeks of exercise every weekday. Each exercise session will last for 12 minutes and will consist of either walk or sit and raise from a chair.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NMES</intervention_name>
    <description>Neuromuscular electrical stimulation of the paretic lower limb during exercise</description>
    <arm_group_label>NMES</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Acute ischemic apoplexy and paresis in lower extremity, verified with picture
             diagnosis (CT/MR) or clinically diagnosed.

          -  Leg palsy equalizes 2-4

          -  Modified Ranking Scale(mRS) =0-1

          -  Cognitive function adequate to participate

        Exclusion Criteria:

          -  Patients with dementia and/or malign diseases

          -  Pregnancy

          -  Epilepsy

          -  Total loss of sensation

          -  Pacemaker

          -  Previous or current blood clot in the leg

          -  Untreated depression

          -  Untreated alcohol or drug abuse

          -  Untreated hypertension

          -  Heart disease which limits function
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Troels Wienecke, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Department of Neurology, Zealand University Hospital, University of Copenhagen, Roskilde, Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Henriette Busk, PT</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept. of Neurology, Zealand University Hospital, and Department of Physiotherapy and Occupational Therapy, Naestved-Slagelse-Ringsted Hospital, Copenhagen University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>SÃ¸ren T Skou, PT, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Southern Denmark and Naestved-Slagelse-Ringsted Hospitals</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gert Kwakkel</last_name>
    <role>Study Chair</role>
    <affiliation>Dept. Rehabilitation Medicine, VU University Medical Center, Amsterdam, The Netherlands</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Neurology</name>
      <address>
        <city>Roskilde</city>
        <zip>4000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>August 28, 2018</study_first_submitted>
  <study_first_submitted_qc>August 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2018</study_first_posted>
  <last_update_submitted>June 22, 2020</last_update_submitted>
  <last_update_submitted_qc>June 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ischemic Stroke</keyword>
  <keyword>Neuromuscular electrical stimulation</keyword>
  <keyword>Activities of daily living</keyword>
  <keyword>Patient reported outcome</keyword>
  <keyword>Fugl Meyer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 11, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/12/NCT03653312/SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

